Marlan D. Walker - 06 Dec 2022 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Role
General Counsel
Signature
/s/ Marlan D. Walker
Issuer symbol
TXMD
Transactions as of
06 Dec 2022
Net transactions value
-$5,185
Form type
4
Filing time
09 Dec 2022, 18:38:31 UTC
Previous filing
31 Mar 2022
Next filing
13 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXMD Common Stock Options Exercise $0 +1,010 +20% $0.000000 6,189 06 Dec 2022 Direct F1
transaction TXMD Common Stock Options Exercise $0 +1,156 +19% $0.000000 7,345 06 Dec 2022 Direct F1
transaction TXMD Common Stock Options Exercise $0 +388 +5.3% $0.000000 7,733 06 Dec 2022 Direct F1
transaction TXMD Common Stock Sale $5,185 -1,048 -14% $4.95 6,685 06 Dec 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXMD Restricted Stock Unit Options Exercise $0 -1,010 -50% $0.000000 1,010 06 Dec 2022 Common Stock 1,010 $0.000000 Direct F1, F4
transaction TXMD Restricted Stock Unit Options Exercise $0 -1,156 -33% $0.000000 2,311 06 Dec 2022 Common Stock 1,156 $0.000000 Direct F1, F5
transaction TXMD Restricted Stock Unit Options Exercise $0 -388 -34% $0.000000 770 06 Dec 2022 Common Stock 388 $0.000000 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 2,554 shares of issuer common stock in settlement of restricted stock units (RSUs).
F2 The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $4.66 through $5.41, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F4 The RSUs vest in three equal installments annually, becoming fully vested on March 30, 2023.
F5 The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.
F6 Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.